-- Earnings Flash (APDN) APPLIED DNA SCIENCES Reports Q3 Revenue $4.3M
4:23PM ET 8/11/2022 MT Newswires...
Quotes Snapshot > APDN
Applied DNA Sciences Inc APDN:NASDAQ
Next Earnings date is expected on
08/11/2022
Last Price$4.52NASDAQ Closing Price as of 4:00PM ET 8/11/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change-0.09(1.95%)
Bid (Size)$4.38 (11)
Ask (Size)$4.45 (3)
Day Low / High$4.33 - 4.90
Volume2.7 M
Read more news Recent News
Applied DNA Sciences Gets Contract Extension to Provide COVID-19 Services; Shares Rise
12:07PM ET 8/09/2022 MT NewswiresApplied DNA Sciences (APDN) said Tuesday that the City University of New York has extended its health services contract for COVID-19 testing and vaccine...
Applied DNA Sciences Closes $12 Million Upsized Public Offering; Shares Sink
1:41PM ET 8/08/2022 MT NewswiresApplied DNA Sciences (APDN) said Monday that it closed a public offering of 3 million shares, together with series A warrants to purchase up to 3 million...
--HC Wainwright Adjusts Applied DNA Sciences' Price Target to $8 from $4, Keeps Buy Rating
12:18PM ET 8/08/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q2 2022 Results - Earnings Call Transcript
11:37PM ET 5/13/2022 Seeking AlphaApplied DNA Sciences, Inc.'s (APDN) CEO James Hayward on Q1 2022 Results - Earnings Call Transcript
6:58PM ET 2/10/2022 Seeking AlphaFlora Ready To Grow Like A Weed
2:43PM ET 1/03/2022 Seeking AlphaApplied DNA Sciences, Inc. (APDN) CEO James Hayward on Q4 2021 Results - Earnings Call Transcript
1:56AM ET 12/10/2021 Seeking AlphaCompany Profile
Business DescriptionApplied DNA Sciences, Inc. engages in the developing and marketing DNA-based technology solutions utilizing LinearDNA, large-scale polymerase chain reaction (PCR) based manufacturing platform. Its proprietary platform produces large quantities of DNA for use in nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets (Biotherapeutic Contract Research and Manufacturing) and for supply chain security, anti-counterfeiting and anti-theft technology purposes. The company was founded in 1983 and is headquartered in Stony Brook, NY. View company web site for more details
| Address | 50 Health Sciences Drive Stony Brook, New York 11790 |
| Phone | +1.631.240.8800 |
| Number of Employees | 59 |
| Recent SEC Filing | 08/10/2022 DEF 14A |
| Chairman, President & Chief Executive Officer | James A. Hayward |
| Chief Operating Officer | Judy Murrah |
| Chief Financial Officer & Controller | Beth M. Jantzen |
| Associate Director-Production | Frank Cipriani |
Company Highlights
| Price Open | $4.59 |
| Previous Close | $4.61 |
| 52 Week Range | $0.62 - 7.35 |
| Market Capitalization | $54.2 M |
| Shares Outstanding | 12.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/11/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.88 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.9 M |
| Net Profit Margin | -95.93% |
| Return on Equity | -135.14% |
Analyst Ratings as of 08/03/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |